Washington HB 1356: Reducing prescription drug costs by eliminating barriers impeding access to biosimilar medicines.

Status: By resolution, reintroduced and retained in present status. (as of 2024-01-08)

State: Washington · Session: 2023-2024 · Bill: HB 1356

Sponsors: Reeves, Doglio, Donaghy, Lekanoff, Reed, Springer

View Washington HB 1356 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.